Diamedica Therapeutics Inc., of Minneapolis, is seeking to raise up to $15 million, including overallotments, in a U.S. IPO. The company's shares trade in Canada on the Toronto Stock Exchange Venture Exchange as DMA and the U.S. Over-the-Counter market as DMCAF. Diamedica plans to list on Nasdaq as DMAC.